Champions Oncology Inc (NASDAQ:CSBR) saw a significant decline in short interest in the month of November. As of November 29th, there was short interest totalling 109,100 shares, a decline of 11.9% from the November 14th total of 123,800 shares. Based on an average daily trading volume, of 45,300 shares, the days-to-cover ratio is presently 2.4 days. Currently, 2.2% of the company’s shares are sold short.
Shares of NASDAQ:CSBR traded up $0.11 during trading hours on Friday, hitting $6.79. 14,500 shares of the company’s stock traded hands, compared to its average volume of 44,027. The firm has a market capitalization of $76.81 million, a P/E ratio of 679.00 and a beta of 1.20. The business has a fifty day moving average price of $5.87 and a 200-day moving average price of $6.70. Champions Oncology has a 1 year low of $4.98 and a 1 year high of $12.80. The company has a debt-to-equity ratio of 2.06, a current ratio of 0.80 and a quick ratio of 0.80.
Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.09). Champions Oncology had a negative return on equity of 48.07% and a negative net margin of 3.61%. The business had revenue of $6.74 million during the quarter, compared to analysts’ expectations of $7.50 million. As a group, equities analysts predict that Champions Oncology will post 0.01 earnings per share for the current year.
CSBR has been the topic of a number of analyst reports. Roth Capital initiated coverage on shares of Champions Oncology in a research report on Friday, September 20th. They set a “buy” rating and a $9.25 price objective on the stock. Zacks Investment Research raised shares of Champions Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, September 24th. Benchmark started coverage on shares of Champions Oncology in a report on Wednesday, November 27th. They issued a “buy” rating and a $11.00 target price for the company. Finally, ValuEngine raised shares of Champions Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $12.42.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
See Also: Average Daily Trade Volume – ADTV
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.